The (68)Ga/(177)Lu-theragnostic concept in PSMA-targeting of metastatic castration–resistant prostate cancer: impact of post-therapeutic whole-body scintigraphy in the follow-up

INTRODUCTION: A new therapeutic option for metastatic castration–resistant prostate cancer (mCRPC) of heavily pre-treated patients lies in (177)Lu-PSMA-617 radioligand therapy. METHODS: On the basis of PSMA-targeted (68)Ga-PSMA-11 PET/CT, 32 consecutive mCRPC patients were selected for (177)Lu-PSMA-...

Descripción completa

Detalles Bibliográficos
Autores principales: Maffey-Steffan, Johanna, Scarpa, Lorenza, Svirydenka, Anna, Nilica, Bernhard, Mair, Christian, Buxbaum, Sabine, Bektic, Jasmin, von Guggenberg, Elisabeth, Uprimny, Christian, Horninger, Wolfgang, Virgolini, Irene
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005064/
https://www.ncbi.nlm.nih.gov/pubmed/31776632
http://dx.doi.org/10.1007/s00259-019-04583-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7005064/
https://www.ncbi.nlm.nih.gov/pubmed/31776632
http://dx.doi.org/10.1007/s00259-019-04583-2

Ejemplares similares